A carregar...
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
BACKGROUND: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the phar...
Na minha lista:
Publicado no: | Drug Des Devel Ther |
---|---|
Main Authors: | , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Dove Medical Press
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527374/ https://ncbi.nlm.nih.gov/pubmed/26257511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S86725 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|